|Podcasts|September 30, 2021
Episode 92: Digesting the GI Market
Author(s)Elaine Quilici, Miranda Schmalfuhs
Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.
Advertisement
Tom McCourt, CEO of Ironwood Pharmaceuticals, discusses his extensive background in gastrointestinal drug development, the current landscape of therapies, and what the future may hold for this space.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments
2
Amgen Acquires Dark Blue Therapeutics in $840 Million Transaction
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
The Real Value Equation: How Humans and AI Create and Destroy Value in Pharma
5